In addition to mitochondria-regulating agent metformin, drugs targeting amino acid metabolism, in particular, the inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, have been applied in multiple clinical trials in combination with anti-PD-1 immunotherapy in melanoma. The gene discussed is PDCD1; the disease is melanoma.